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A Macrocyclic Calpain Inhibitor Slows the Development of
Inherited Cortical Cataracts in a Sheep Model
James D. Morton,1 Hannah Y. Y. Lee,1 Josh D. McDermott,1 Lucinda J. G. Robertson,1
Roy Bickerstaffe,1 Matthew A. Jones,2 James M. Coxon,2 and Andrew D. Abell*,2
PURPOSE. We used sheep with an autosomal dominant gene for
cortical cataract as an animal model to evaluate novel
macrocyclic calpain inhibitors with potential for the medical
treatment of human cataract.
METHODS. The macrocyclic aldehyde, CAT811, identified
previously as a calpain inhibitor that prevents calcium-induced
opacification in cultured sheep lenses, was tested for its ability
to protect cytoskeletal proteins from calpain proteolysis.
CAT811 and its alcohol analogue, CAT505, were formulated
separately into ointments, and each was applied twice daily to
the right eye of sheep with early cataracts for five months.
Progress of cataracts in the sheep was determined by
ophthalmologic examination and comparison with a matched
sample of sheep treated similarly with ointment that did not
contain the active ingredient.
RESULTS. The novel macrocyclic aldehyde, CAT811, was able to
inhibit calpain proteolysis of lens cytoskeletal proteins at
micromolar concentrations. When applied topically to the eyes
of sheep, CAT811 was able to slow cataract development by
27% in the initial three months of treatment (P < 0.05). Its
alcohol analogue, CAT505, was not able to slow cataracto-
genesis significantly.
CONCLUSIONS. The inherited sheep cataract provides a repro-
ducible model of cortical cataract over a time scale of several
months. The data reported here, using this model, demon-
strated the potential of the macrocyclic calpain inhibitor,
CAT811, to act as a therapeutic for treatment of cortical
cataract. (Invest Ophthalmol Vis Sci. 2013;54:389–395) DOI:
10.1167/iovs.12-11088
Cataracts are the leading cause of blindness in humans.
1
They result from many causes, but the outcome in all cases
is loss of lens transparency. Cataracts can be classified by their
location in the lens, with the two most common types being
cortical and nuclear.2
The lens nucleus consists of quiescent mature fiber cells
that lack organelles and thereby rely on a nonoxidative
metabolism.3 In contrast, the outer cortex is the site of intense
activity where cuboidal epithelial cells differentiate into
elongated fibrous cells. During this process, which has been
likened to a partial apoptosis,4 the surface area-to-volume ratio
of the cells increases dramatically and the organelles are lost.
Associated with these cellular changes are dramatic alterations
in protein synthesis and cytoskeleton rearrangement.
A rise in the intracellular concentration of Ca2þ results in
enhanced degradation of proteins, which is significant in
cortical, but not in nuclear cataracts.5 This has led to the
hypothesis that inappropriate activation of the Ca2þ-dependent
cysteine proteases or calpains (EC 3.4.22.17) is important in
cortical cataract.6 The overactivation of calpains has been
implicated in a number of other human diseases,7,8 and there is
extensive evidence that cytoskeletal and regulatory proteins
are preferred calpain substrates.9 Exogenous calpain inhibitors
have been used to investigate the role of calpains in human
disorders,10 including cataract formation.11 While a number of
calpain isoforms have been reported in the lens, calpain 2 is
the dominant isoform in human12 and sheep13 lenses.
Exogenous calpain inhibitors could provide an attractive
alternative to surgery for the treatment of cataract given the
likely role of calpains in their development. A number of linear
peptidometric inhibitors have shown some promise in lens
culture and in vivo animal experiments.13,14 Our current study
tests macrocyclic compounds that are constrained into a b-
strand conformation15 that is known to favor binding to a
protease, in this case calpain.16 Several of these compounds
have been shown to be excellent in vitro calpain inhibitors17
with the best being CAT811, a compound containing a C-
terminal aldehyde that had an IC50 of 30 nM for calpain 2. The
analogue with a less reactive alcohol in place of the aldehyde
(Fig. 1, CAT505) also showed promise with an IC50 of 700 nM.
Both compounds showed no inhibitory activity against papain,
a-chymotrypsin, and pepsin when tested at concentrations up
to 50 lM.17 However, both were potent inhibitors of cathepsin
B with IC50s of 70 and 300 nM, respectively. Both inhibitors
preferentially inhibited calpain 2, the predominant calpain
isoform in ovine lenses,13 over calpain 1.17
Potential drugs for treating cataract already have been
tested in a number of animal models and also with cultured
lenses from several animal species.18–20 Rodent lenses have
been the most commonly used, but these show significant
biochemical and anatomic differences from human lenses.21 By
comparison, the sheep lens is similar anatomically to the
human lens with its proteins showing greater homology to
human lens proteins than those of rodents.22 Sheep lenses,
therefore, are a particularly useful model.23 Previous work has
shown that CAT811 is able to prevent calcium-induced cataract
formation in lens culture,17 which confirmed that the
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inhibitors can penetrate the lens. This is important, since
earlier research has shown that the opacification involves inner
fiber cells. This experiment also confirmed that the aldehyde
inhibitor was effective in the high protein concentrations
within the lens.
The sheep model used in our study involves a dominant
mutation on chromosome 6 of sheep, which has been shown
to lead to a reproducible inherited cortical cataract24 over a
period of several months. Two earlier trials in this sheep model
showed that acyclic calpain inhibitors were able to slow the
progression of cataract for up to a month.13,23 We now report
on the ability of the macrocyclic inhibitor CAT811 to prevent
proteolysis of lens cytoskeletal proteins, and compare the
ability of CAT811 and its alcohol analogue, CAT505, to slow
cataract progression in this sheep model during an extended in
vivo trial.
MATERIALS AND METHODS
Synthesis and Formulation of Calpain Inhibitors
CAT811 and CAT505 were synthesized as described previously17 and
purified by HPLC. For the in vivo trial, they each were formulated into a
crystal-free ointment (1% inhibitor molecule, 30% cetyl stearyl alcohol,
35% lanolin, and 34% paraffin wax). Ointment without inhibitor was
used for the controls. These were partitioned into 1 mL syringes and
stored at 48C for up to 1 to 2 months before use.
Animals
All animal procedures were performed in accordance with Lincoln
University Animal Ethics Protocol AEC#154 as reviewed by the New
Zealand Animal Ethics Committee, and in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision Research.
Lenses for the cell-free system were from 9- to 11-month-old lambs
collected from the local abattoir. The lambs used in the in vivo trials
were from the Lincoln University cataract flock.13 At the start of the in
vivo trial they were two months old with a mean weight of 21.5 6 4.6
kg (N¼ 63 lambs).
Calpain Inhibitor Assay in a Cell-Free System
A urea soluble fraction (USF) of the lens cortex was used to evaluate
the effectiveness of the inhibitors in preventing cytoskeletal protein
degradation. The outer cortex of six fresh sheep lenses was removed
from the solidified nucleus tissue, yielding cortex tissue samples of an
average wet weight of 495 6 0.01 mg. The separated cortex tissue
then was homogenized in one volume of 20 mM Tris-HCl buffer, pH
7.5, 1 mM EGTA, 1 mM EDTA, 2 mM DTT containing Complete, Mini
protease inhibitor cocktail (Roche, Mannheim, Germany) prepared as
per company instructions. This solution was centrifuged at 15,000g for
1 hour. The pellet was washed three times by resuspension in 1 mL of
homogenization buffer without protease inhibitors followed by
recentrifugation. The washed pellet was resuspended in 100 lL of 6
M urea and centrifuged at 15,000g for 1 hour. The supernatant (USF)
was collected and its protein content determined (BCA Protein Assay
Kit; Pierce, Rockford, IL). The protein concentration of the USF then
was adjusted to 10 mg/mL by the addition of 6 M urea and the solution
stored at 208C.
Calpain 2 was purified from ovine lung. Briefly, 300 g of fresh ovine
lung was homogenized and the calpains precipitated in 50%
ammonium sulfate (Sigma-Aldrich, St. Louis, MO). This was followed
by a sequence of hydrophobic, ion-exchange, and dye ligand
chromatography. The calpains were separated from their inhibitor
calpastatin on a 300 3 26 mm hydrophobic chromatography column
(Phenyl Sephraose; GE Healthcare Bio-Sciences AB, Uppsala, Sweden).
The column was loaded and washed in 0.5 M NaCl to elute calpastatin,
and then the calpains were eluted in the absence of NaCl. The pooled
calpain was loaded onto a 3503 26 mm ion-exchange chromatography
column (DEAE-Sepharose; GE Healthcare Bio-Sciences AB) and eluted
with a 500 mL 0.1 to 0.4 M NaCl linear gradient. This separated calpain
1 and 2. The pooled calpain 2 fractions then were purified further on a
130 3 16 mm dye ligand chromatography column (Reactive Red
Agarose; Sigma-Aldrich) washed with 0.5 M NaCl and eluted without
salt.
One mg of USF was incubated at 208C for l hour with calpain 2 in
the presence of 1.2 mM Ca2þ and inhibitor concentrations varying from
0 to 10 lM. The proteins were separated by electrophoresis on 4% to
12% Bis-Tris PAGE gels (NuPAGE; Invitrogen, Carlsbad, CA), stained
with GelCode Blue (Pierce), and the optical density measured by Gel
Doc EQ and Quantity One (Bio-Rad Laboratory, Hercules, CA). The
results are the average of duplicate determinations.
The identity of the cytoskeletal proteins was confirmed by
immunoblotting. After electrophoresis the proteins were transferred
to a polyvinylidine difluoride (PVDF) membrane and incubated with
the appropriate antibodies, namely polyclonal antispectrin (H-105) and
monoclonal antivimentin (V9), sourced from Santa Cruz Biotechnology,
Inc. (Santa Cruz, CA) and monoclonal antifilensin (Sigma-Aldrich).
Immunoreactivity was visualized using the appropriate secondary
antibodies and the alkaline phosphatase Conjugate Substrate Kit (Bio-
Rad Laboratories).
Testing Macrocyclic Calpain Inhibitors In Vivo in a
Sheep Model
Overall Trial Design. Breeding of four sires with ovine heritable
cataracts produced 208 lambs. Their eyes were assessed between the
ages of one to two months to select 63 lambs that had right eyes with
cataract scores of 1 to 3 (Table 1). This population was divided, by an
independent statistician, into three comparable groups based on their
body weight, sex, and cataract score. The groups consisted of a control
group, a group for testing with CAT811, and a group for testing with
CAT505.
The protocol specified the key data point to be that after three
months of treatment. This was based on previous experience of the
FIGURE 1. Macrocyclic calpain inhibitors CAT505 (molecular weight
[MWt]¼ 525.64) and CAT811 (MWt¼ 523.6).
TABLE 1. Progression of the Ovine Inherited Cataract
Stage Description
0 Normal ovine lens
1 Small opacity detected at either the anterior or posterior
suture line
2 Small opacities detected at both suture lines
3 Opacities involved in 0% to 30% of the lens
4 Opacities involved in 33% to 66% of the lens
5 Total immature cataract—reflection from retina still visible
6 Total mature cataract—no reflection from retina
7 Hypermature cataract, displaying partial absorption of
severely opaque lenses, leaving a fluid-filled lens remnant
Each number represents the stage of cataractogenesis (0–7) used to
describe and score cataracts for the in vivo inhibitor treatments.
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progression of sheep cataract to give the maximum chance of
observing differences in rate of cataract formation with treatment.
All trial lambs were grazed together and yarded twice daily for
treatment of the right eye only with 17 to 23 mg of ointment
containing 170 to 230 lg of either CAT811 or CAT505. All lambs in the
treatment trials were yarded at monthly intervals to assess cataract
scores in the treated and untreated eyes by an independent veterinary
ophthalmologist who was unaware of which eyes had been treated.
The assessment was done using a slit-lamp microscope (Kowa SL-T;
Kowa Co. Ltd., Tokyo, Japan) in a darkened room as described
previously.13 The progress of cataract development was scored using
an established 8-point scale23 as described in Table 1.
Animal Health. Condition scores of the sheep were measured at
the start and the end of the 5-month trial. Three lambs from each
treatment group had 5 mL blood samples taken by venipuncture at the
start and end of the trial. These were centrifuged (1200g for 15
minutes) and the serum stored at 808C before being sent to a
veterinary pathology laboratory for biochemical analysis (Gribbles
Veterinary, Christchurch, NZ). Live body weights of the sheep were
monitored and recorded throughout the trials.
Statistical Analysis
Significant decreases in loss of band density of cytoskeletal proteins
during the cell-free assay were determined by independent t-tests
comparing the mean band density in the presence and absence of
inhibitor (Minitab, version 15; Minitab Inc., State College, PA).
Independent t-tests were used in the in vivo trial to determine whether
the calpain inhibitors slowed cataract progression in the treated
animals by comparing the mean changes between each treatment with
the control group. A 2-tailed P value < 0.05 was taken to indicate
statistical significance.
An earlier trial, where CAT811 was applied as an ointment to one
eye of lambs, revealed no observable difference between the treated
and untreated eye of each individual lamb (Morton JD, Lee HYY,
Robertson LJG, unpublished data, 2006). However, the rate of cataract
progress was slower in those lambs treated with CAT811 relative to
those treated with the acyclic inhibitor, CAT0059,23 indicating a
pathway for crossover between the eyes. As there was no evidence of a
difference between the treated right eye and the left eye with either
CAT505 or CAT811 in the current trial, the cataract scores of both eyes
were combined for the analyses.
RESULTS
CAT811 Inhibits Proteolysis of Cytoskeletal
Proteins
The ability of CAT811 to inhibit the degradation of key
cytoskeletal proteins also was assessed in vitro. The presence
of spectrin, filensin, and vimentin in the USF of sheep lens was
confirmed by immunoblotting (Fig. 2). When this fraction was
incubated with purified ovine calpain 2 and 1.2 mM Ca2þ,
marked proteolysis of all three proteins was observed (Fig. 3).
This did not occur when a similar fraction was incubated with
FIGURE 2. Immunoblots for vimentin, filensin, and spectrin in the urea soluble fraction (10 lg/lane) from the cortical region of normal sheep
lenses. Fragments of vimentin are marked (arrowheads). Mw, molecular markers.
FIGURE 3. SDS PAGE (4%–12%) protein profiles with the urea soluble fraction of sheep lens illustrating the efficacy of CAT811 in preventing calpain
proteolysis of lens cytoskeletal proteins. The arrows indicate intact spectrin (280 kDa), filensin (115 kDa), and vimentin (57 kDa). The USF of sheep
lens was incubated with purified sheep calpain 2 and 1.2 mM Ca2þ in the presence of 0, 0.1, 1.0, and 10 lM of CAT811. Ca2þ, USF incubated with
1.2 mM Ca2þ; Cal, USF with purified ovine calpain 2.
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either Ca2þ or calpain alone. The macrocyclic calpain inhibitor,
CAT811, was shown to protect significantly intact spectrin and
filensin from Ca2þ-induced calpain degradation at a concentra-
tion of 0.1 lM (Table 2). Vimentin was the most sensitive of the
three cytoskeletal proteins to proteolysis by calpain 2 and
required 10 lM CAT811 to protect it from proteolysis.
Evaluation of CAT811 and CAT505 Efficacy with
Ovine Inherited Cataract
The two compounds were tested for their ability to slow
cataract progression when applied twice daily as an ointment
to the sheep. The lambs with cataracts were divided into three
groups to receive separately placebo, CAT811, or CAT505
(Table 3). The cataract scoring system was used to evaluate the
rate of cataract development over the treatment periods (Table
1). At the start of the trial almost 88% of the lenses were scored
at either 1 or 2.
The lenses of the lambs were scored at approximately
monthly intervals over a period of five months. The first
observation of note was that there was no difference in mean
cataract score between treated and untreated eyes within each
group, as we had noted previously. As discussed earlier, this
provides evidence that the compounds were affecting both
eyes. Therefore, all results reported herein are mean cataract
scores for both eyes of each sheep within each group.
During the lens analysis, the veterinary ophthalmologist
determined that one animal (228) in the placebo group had
been misdiagnosed as its initial opacity had actually cleared
with time. Thus, the data from this animal were removed from
the trial. Two other lambs, one in the placebo group (130) and
one in the CAT811 treatment group (209), showed no change
in their opacities over the five months and also were removed
from the analysis.
The predetermined key point for analysis of efficacy was 3
months. During this time the mean lens opacity in the control
group increased from 1.82 to 4.66, a change in score of 2.84.
Over the same period the score of the lambs treated with
CAT811 increased by 2.08, which represents a 27% slowing in
the development of cataracts (P < 0.05, Fig. 4). The opacity of
lenses in lambs treated with CAT505 increased by 2.26.
However, there was significant variation in progression within
each group and in this case the difference from the placebo
was not significant (P ¼ 0.12).
The lambs were between 7 and 8 months of age by the end
of the trial, and 75% had mature cataracts (stages 5–7, Fig. 5).
This rate of progression of cataract was within the range
reported in earlier trials involving similar animals from the
Lincoln cataract flock.13,23
The lambs were treated for a further two months, with no
further significant differences between drug-treated and
placebo groups apparent after three months. This was
considered to be a result of the plateau in the control group,
since a high proportion of these lambs already had mature
cataract.
All three groups showed similar growth with all animals
maintaining their condition through the course of the trial
(Table 3). As such, the prolonged daily treatment, with either
CAT811 or CAT505, did not result in any apparent harm to the
lambs.
Analysis of serum enzymes revealed no evidence of liver
damage with either the CAT811- or CAT505-treated sheep
(Table 4). Although the values of aspartate transaminase (AST)
increased with age, all were within the normal range and while
gamma glutamyl transferase (GGT) was slightly above the
normal range, the highest values were found in the placebo
animals.
There also was no evidence of either kidney damage or
increased protein turnover with any of the treatments. Serum
levels of creatinine were low in all samples and urea was
within the normal range. Both values increased with increasing
TABLE 2. Efficacy of CAT811 in Preventing Calpain Proteolysis of Lens Cytoskeletal Proteins
Proteins N USF
Concentration of CAT811
0 lM 0.1 lM 1.0 lM 10 lM
Vimentin 2 1.00 6 0.01 0.54 6 0.04 ND 0.69 6 0.07 1.00 6 0.08*
Spectrin 4 1.00 6 0.01 0.65 6 0.04 0.76 6 0.15 0.94 6 0.04* 1.23 6 0.01*
Filensin 4 1.00 6 0.03 0.82 6 0.08 0.87 6 0.02 0.91 6 0.05* 1.07 6 0.01*
The mean band optical density (6 SEM) spectrin, filensin, and vimentin following proteolysis in the presence of different concentrations of
CAT811 are expressed as a proportion of the density in USF. No intact vimentin was visible following application of 0.1 lM 811 (ND).
* Indicates that these inhibitor treatments resulted in a significant decrease in proteolysis for that protein (P < 0.05, two-sample t-test).
TABLE 3. Mean Cataract Scores of Both Eyes, Live Weight of Lambs,
and Condition Scores of All Experimental Sheep (6 SD) during the In
Vivo Drug Application
Mo
Treatment Group
Placebo CAT811 CAT505
N of sheep 19 20 21
Mean cataract scores 0 1.82 6 0.89 1.80 6 0.79 1.71 6 0.72
3 4.66 6 1.51 3.88 6 1.53 3.98 6 1.46
5 5.58 6 1.24 5.00 6 1.52 5.21 6 1.08
Live body weight, kg 0 21.0 6 4.1 21.6 6 5.6 22.1 6 4.4
3 32.7 6 5.0 31.8 6 5.8 33.8 6 4.8
Condition scores 0 2.1 6 0.4 2.2 6 0.5 2.1 6 0.4
5 2.0 6 0.4 2.1 6 0.4 2.1 6 0.3
FIGURE 4. Treatment of cataract ovine lenses with CAT811 and
CAT505. The graph shows the difference in mean cataract scores (6
SEM), as measured by the independent veterinary ophthalmologist,
between the start of the trial and after three months (96 days). Two tail
t-test, *P < 0.05.
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age of the animals, but there was no difference between the
treatment groups.
DISCUSSION
Our report compares the effectiveness of two macrocyclic
calpain inhibitors, CAT811 and CAT505. The conformational
constraint introduced by the macrocycle of this new
generation of inhibitors appears to offer improved potency
and selectivity compared to acyclic inhibitors. These macro-
cyclic structures also have improved biostability with
improved resistance to other proteases. CAT811, with an
aldehyde warhead, was the most effective inhibitor in vitro
and it showed selectivity for calpain 2, the dominant calpain
isoform in human and sheep lenses. CAT505 was less
effective in vitro, but it may be useful in vivo and in other
indications as the alcohol is less reactive than the aldehyde of
CAT811.
Cytoskeletal proteins are important particularly in lenses as
the transition from epithelial cells to elongated fiber cells relies
on extensive synthesis and rearrangement of the cytoskeleton.
These proteins also are important physiologic substrates for
calpain. Several investigators have proposed that calpain’s
involvement in human cataract may be a result of its disruption
of the cytoskeleton.13,20,25 In a proteomic analysis of changes
in crystallins and other lens proteins during formation of the
ovine hereditary cataract, cytoskeletal proteins were lost from
the water-insoluble fraction.26 Other research23 has shown that
ovine lens spectrin, the anchor for the actin network, and the
two intermediate filament proteins, filension and vimentin, are
proteolyzed by ovine calpain 2. In our study, we have shown
that CAT811 is able to inhibit this proteolysis. The high
sensitivity of vimentin also was noted in earlier research where
1.0 lM of the acyclic inhibitor SJA6017 was protective.23
The inhibitors were administered as ointments to lambs
with inherited cataracts over a period of five months. The gene
causing cataract is inherited in an autosomal dominant manner
FIGURE 5. The cataract scores are shown for each group at the start of the trial, and after three months (96 days) and five months of treatment (153
days).
TABLE 4. Biochemical Analysis of Serum Markers of Toxicity (Means 6 SEM)
Treatment AST, IU/L GGT, IU/L Creatinine, lmol/L Urea, mmol/L
Normal range 44 to 123 0 to 55 105 to 170 3.9 to 11.3
Start of trial
Placebo 70.3 6 12 75 6 8.5 58 6 8.9 5.53 6 0.84
CAT811 77 6 13 54.7 6 5.8 58.33 6 2.8 5.2 6 0.12
CAT505 89.33 6 5.2 63.67 6 0.88 52.67 6 4.1 5.17 6 0.64
End of trial
Placebo 100 6 8.6 75.3 6 12 76.67 6 4.3 10.17 6 0.97
CAT811 107.7 6 12 63.7 6 4.7 75 6 5.1 9.63 6 0.97
CAT505 122.7 6 10 38.7 6 7.6 70.67 6 5.6 10.1 6 1.5
Serum samples were taken from three animals from each treatment group at the beginning and end of the five-month trial. They were analyzed
for liver function with AST and GGT, and for kidney and muscle damage with creatinine and urea.
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with limited penetrance.24 This meant that when a ram
carrying the mutation is mated with normal-eyed ewes
approximately 40% of the offspring will have cataract.
Selection of animals for this trial was completed by a veterinary
ophthalmologist when the lambs were less than 2 months old
and most of the lenses were scored with small opacities.
Although this normally is predictive of inherited cataract, one
of the 64 lambs identified was later diagnosed not to have
cataract and another two did not progress from the initial
opacity over the five months of the trial. In comparison, all the
other lenses progressed at least two grades with three quarters
having mature cataracts. On this basis these three animals were
removed from the trial.
Although the ointment was administered only to the right
eye of the lambs, the analysis compared all lenses from treated
sheep to those of the controls. This was done because there
was no observable difference in the rate of progression
between treated and untreated eyes within a treatment group.
The assumption was made that the compounds were able to
transfer to the other eye, with such a transfer having been
reported in humans using topical agents for glaucoma27 and
also has been found in this ovine model with the acyclic
calpain inhibitor, SJA6017.13 Research to confirm this process
using a tritiated analogue of CAT505 will be published
separately.
The inherited propensity for cataract in sheep described
here provides a natural large mammal model of human
cataract. Normal progression of cataract leads to mature
cataract in lambs at 6 to 8 months of age. This then provides a
suitable accelerated model for the evaluation of potential
topically applied treatment of cataract in humans. Earlier in
vivo trials with the acyclic calpain inhibitors SJA601713 and
CAT005923 demonstrated their ability initially to slow
progression for up to a month. In this research, CAT811
was shown to slow the progression of cortical cataracts in
these lambs by 27% over three months relative to untreated
animals. This is a significant result in the context of the
relatively rapid progression of cataracts in this model as
compared to humans. Cortical cataracts are the most
common type of human cataract2 and usually take many
years to develop. A treatment that slows this progression by a
similar amount could greatly delay or even remove the need
and urgency for surgery. It has been estimated that delaying
surgery for 10 years would halve the requirement for cataract
surgery.28
The potential of CAT811 to prevent or slow cataract
development in humans is dependent on the importance of
calpain in the human lens. Calpain 2 has been shown to be the
dominant isoform in human lens12 and calcium-induced
proteolysis was confirmed in human lens culture model of
cataract.6 It has been proposed that there was only limited
activity of the calpains in primate lenses based largely on the
lack of crystallin proteolysis.29 However, a more recent study
from the same group25 has confirmed earlier results that the
role of calpain may be targeted to key cytoskeletal proteins in
the epithelial cell layer. This suggests that calpain inhibitors
may be useful in treating human cataracts. CAT811 also is a
potent inhibitor of the lysosomal protease, cathepsin B,17 but is
more likely to be acting as a calpain inhibitor because mature
lens fiber cells lack lysosomes and within the epithelium the
target proteins are in the cytoplasm.
In conclusion, the topical application of CAT811 to an eye
is a promising approach for slowing the development of
cataracts. This research has shown it is effective and safe in a
prolonged trial in a large animal model. It now must be tested
in human lenses and also consideration given to a more
effective delivery system.
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